AstraZeneca PLC

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its global headquarters in Cambridge, England. Its R&D is concentrated in Cambridge, Gaithersburg, Maryland, U.S. and Mölndal, Sweden. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.

The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).

AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.

Type:                     Public limited company

Traded as:           LSE: AZN; NYSE: AZN; Nasdaq Stockholm: AZN

FTSE 100:             Component

Industry:              Pharmaceutical; Biotechnology

Predecessors:     Astra AB;    Zeneca Group plc

Founded:            6 April 1999; 21 years ago

Headquarters:   Cambridge, UK

Area served:      Global

Products:             Pharmaceutical products

Subsidiaries:       MedImmune

Website:              www.astrazeneca.com